Serum Lipid Associated Sialic Acid in Different Human Malignances: Preliminary Results

  • L. Santamaria
  • N. Katopodis
  • G. Santagati
  • A. Bianchi
  • R. Pizzala
  • C. C. Stock


The documentation of alteration in the metabolism of tumor cell surface glycoproteins and sialoglycolipids1,2 has encouraged the study of these components as possible tumor marker in blood. Recent studies show that mean values for total bound sialic acid3,4,5,6 or protein bound sialic acid7,8 were higher in cancer patients than in normal subjects. Sialic acid levels correlated with stage of disease9,7, tumor burden5,10 degree of metastasis and recurrence of disease11. In some cases protein-bound sialic acid showed only limited correlation with the clinical disease status of the patient8. A serious limitation of this procedure was the finding that sialic acid levels were also elevated in other inflammatory or chronic diseases 9,5,12 resulting in false positive findings.


Breast Cancer Gastric Cancer Sialic Acid Neuraminic Acid Total Sialic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. I. Hakomori, Glycolipids of tumor cell membrane. Adv. Cancer Res. 18: 265–315 (1974).Google Scholar
  2. 2.
    V. N. Nigam, A. Cantero, Polysaccharides in cancer:glycoproteins and glycolipids. Adv. Cancer Res. 17: 1–80 (1973).CrossRefGoogle Scholar
  3. 3.
    A. Hogan-Ryan, J. J. Fennelly, J. Jones, B. Cantevell, M. J. Duffy, Serum sialic acid and CEA concentration in human breast cancer. Br. J. Cancer 41: 587–592 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    H. K. B. Silver, K. A. Karim, F. A. Salinas, Development of an improved assay for N-acetil neuraminic acid (NANA) using high performance liquid chromatography (Abstr) Proc. Am. Ass. Cancer Res. 22: 185 (1981).Google Scholar
  5. 5.
    H. K. B. Silver, D. M. Rangel, D. L. Morton, Serum sialic acid elevations in malignant melanoma patients. Cancer 41: 1497–1499 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    R. J. Shamberger, Sialic acid in cancer patients (Abstr). Proc. Am. Ass. Cancer Res. 22: 21 (1981).Google Scholar
  7. 7.
    A. J. Moss, N. K. Bissada, C. M. Boyd, W. C.Hunter,Significance of protein-bound neuraminic acid level in patients with prostatic and bladder carcinoma. Urology 13: 182–184 (1979).PubMedCrossRefGoogle Scholar
  8. 8.
    J. E. Mrochek, S. R. Dinsmore, D. C. Tormey, T. P. Waalkes, Protein-bound carbohydrates in breast cancer: liquid chromatographic analysis for mannose, galactose,fucose and sialic acid in serum. Clin. Chem. 2: 1516–1521.Google Scholar
  9. 9.
    R. A. L. MacBeth, J. G. Bekasi, Plasma glycoprotein in various diseases states including carcinoma. Cancer Res. 22: 1170–1176 (1962).Google Scholar
  10. 10.
    H. K. B. Silver, K. A. Karim, E. L. Archibald, F. A. Salinas, Serum sialic acid and sialyltransferase as monitor of tumor burden in malignant melanoma patients. Cancer Res. 39: 5036–5042 (1979).PubMedGoogle Scholar
  11. 11.
    O. Kirikuta, R. Bojan Comes, R. Cristian, Significance of serum fucose, sialic acid, haptoglobine and phospholipide levels in the evolution and.?treatment of breast cancer.Arch. Geschivultforsch 49: 16–112 (1979).Google Scholar
  12. 12.
    A. Lipton, H. A. Harvey, S. Delong et Al., Glycoproteins and human cancer 1. Circulating levels in cancer serum. Cancer 43: 1766–1771 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    A. M. Dnistrian, V. P. Skipski, M. Barclay, E. S. Essner and C. C. Stock: Gangliosides of plasma membranes from normal rat liver and Morris Hepatoma. Biochem. Biophis. Res. Comm. 64: 367–375 (1975).CrossRefGoogle Scholar
  14. 14.
    V. P. Skipski, N. Katopodis, J. S. Prendergast and C. C.Stock, Gangliosides in blood serum of normal rats and Morris hepatoma 5123 tc-bearing rats. Biochem. Biophis. Res. Comm. 67: 1122–1127 (1975).CrossRefGoogle Scholar
  15. 15.
    F. M. Kloppel, T. W. Keenan, M. J. Freeman, D. J. Moore, Glycolipids-bound sialic acid in serum: increased levels in mice and human bearing mammary carcinomas. Proc. Natl. Acad. Sci. 74: 3011–3013.Google Scholar
  16. 16.
    F. M. Kloppel, C. P. Franz, D. J. Moore, R. C. Richardson, Serum sialic acid levels increase in tumor bearing dogs. Am. J. Vet. Res. 39: 1377–1380 (1978).PubMedGoogle Scholar
  17. 17.
    E. E. Lengle, Increased level of lipid bound sialic acid in thymic lymphocytes and plasma from leukemic AKR/J mice. J. Natl. Cancer. Inst. 62: 1565–1567 (1979).PubMedGoogle Scholar
  18. 18.
    N. Katopodis, Y. Hirshaut and C. C. Stock, Spectrophotometric assay of total lipid-bound sialic acid in blood plasma of cancer patients and asymptomatic healty individuals. Proc. Am. Assoc. Cancer. Res. 21: 182 (1980).Google Scholar
  19. 19.
    U. Dunzendorfer, N. Katopodis, A. N. Dnistrian, C. C. Stock, M. K. Schwartz, W. E. Jr. Withmore, Plasma lipid bound sialic acid in patients with prostate and bladder cancer. Investigative Urology 19, 3 194–196 (1981).PubMedGoogle Scholar
  20. 20.
    D. Kostic and F. Bucheit, Gangliosides in human brain tumor. Life Sci. 9: 589–596 (1970).CrossRefGoogle Scholar
  21. 21.
    A. Keranen, M. Lempinen and K. Puro; Gangliosides pattern and neuraminic acid content of human gastric and colonic carcinoma. Clin. Chem. Acta 70: 103–112 (1976).CrossRefGoogle Scholar
  22. 22.
    J. Portoukalian, G. Zwingelstein, J. F. Dore,4th International symposium on malignant melanoma- Lyon- France- (1976).Google Scholar
  23. 23.
    J. Hildebrand, P. A. Stryckmans and J. Vanouche, Gangliosides in leukemic and non-leukemic human leukocites. Biochem. Biophis. Acta 260: 272–278 (1972).Google Scholar
  24. 24.
    N. Katopodis and C. C. Stock, Improved method to determine lipid bound sialic acid in plasma or serum. Res. Comm. Chem. Pathol. Pharm. 30: 171–180 (1980).Google Scholar
  25. 25.
    N. Katopodis, Y. Hirshaut, N. L. Geller and C. C. Stock, Lipid associated sialic acid test for the detection of human cancer. Cancer Res. 42: 5270–5275 (1982).PubMedGoogle Scholar
  26. 26.
    A. M. Dnistrian, K. Morton, N. Katopodis, A. Fracchia and C. C. Stock, Serum lipid-bound sialic acid as a marker in breast cancer. Cancer 50: 1815–1819 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • L. Santamaria
    • 1
    • 2
  • N. Katopodis
    • 3
    • 4
  • G. Santagati
    • 1
    • 2
  • A. Bianchi
    • 1
    • 2
  • R. Pizzala
    • 1
    • 2
  • C. C. Stock
    • 3
    • 4
  1. 1.C. Golgi Institute of General PathologyCentro Tumori Medical ClinicPaviaItaly
  2. 2.Institute of Pharmacology IIUniversity of PaviaPaviaItaly
  3. 3.Sloan Kettering Institute for Cancer ResearchNew YorkUSA
  4. 4.N-K LaboratoriesStamfordUSA

Personalised recommendations